Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
0(0%)
Results Posted
15%(2 trials)

Phase Distribution

Ph phase_4
8
57%
Ph phase_1
4
29%
Ph phase_3
1
7%
Ph phase_2
1
7%

Phase Distribution

4

Early Stage

1

Mid Stage

9

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
4(28.6%)
Phase 2Efficacy & side effects
1(7.1%)
Phase 3Large-scale testing
1(7.1%)
Phase 4Post-market surveillance
8(57.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.9%

13 of 14 finished

Non-Completion Rate

7.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(13)
Terminated(1)

Detailed Status

Completed13
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (28.6%)
Phase 21 (7.1%)
Phase 31 (7.1%)
Phase 48 (57.1%)

Trials by Status

completed1393%
withdrawn17%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_1

Clinical Trial of PCV24 in Children Aged 2-17 Years

NCT06550830
completedphase_1

Extension Safety and Immunogenicity Study of GPNV-001

NCT05982314
completedphase_4

PCV13 + Hepatitis a Vaccine for Adults

NCT01926860
completedphase_1

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

NCT05667740
completedphase_3

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06550830Phase 1

Clinical Trial of PCV24 in Children Aged 2-17 Years

Completed
NCT05982314Phase 1

Extension Safety and Immunogenicity Study of GPNV-001

Completed
NCT01926860Phase 4

PCV13 + Hepatitis a Vaccine for Adults

Completed
NCT05667740Phase 1

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Completed
NCT03439657Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Completed
NCT04830358Phase 1

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

Completed
NCT01735084Phase 4

Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life

Completed
NCT02787863Phase 4

Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology

Completed
NCT02918708Phase 4

Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants

Withdrawn
NCT03838497Phase 4

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

Completed
NCT01174849Phase 4

Pneumococcal Vaccines Early and in Combination

Completed
NCT01781871Phase 4

Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients

Completed
NCT02215863Phase 4

Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

Completed
NCT01847781Phase 2

PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14